» Articles » PMID: 9020878

Neuropeptide Y Modulates ATP-induced Increases in Internal Calcium Via the Adenylate Cyclase/protein Kinase A System in a Human Neuroblastoma Cell Line

Overview
Journal Biochem J
Specialty Biochemistry
Date 1997 Jan 15
PMID 9020878
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The modulatory effects of neuropeptide Y (NPY) on ATP-induced increases in cytosolic free-calcium concentration ([Ca2+]i) were investigated in the CHP-234 human neuroblastoma cell line. Pretreatment of cells with 100 nM NPY potentiated the increase in [Ca2+]i evoked subsequently by 20 microM ATP, compared with initial application of ATP in a control experiment, whereas a similar pretreatment with 1 microM NPY attenuated the subsequent response to ATP. Both actions of NPY were completely blocked by H-89 [N-[2-((3-(4-bromo-phenyl)-2-propenyl)-amino)-ethyl]-5 isoquinoline sulphonamide dihydrochloride], a selective antagonist of protein kinase A. The effects of 100 nM NPY were mimicked by H-89, while forskolin and 8-Br-cAMP mimicked the effects of 1 microM NPY. Both basal and forskolin-stimulated cAMP levels were inhibited by 100 nM NPY and by 100 nM NPY(13-36), a selective agonist of the NPY Y2-receptor subtype. In contrast, at 1 microM such inhibition was not observed for either NPY or NPY(13-36). It is concluded that NPY has a biphasic modulatory effect on increases in [Ca2+]i produced by ATP, which probably involves the cAMP/protein kinase A cascade.

Citing Articles

Neuropeptide Y Peptide Family and Cancer: Antitumor Therapeutic Strategies.

Sanchez M, Rodriguez F, Covenas R Int J Mol Sci. 2023; 24(12).

PMID: 37373115 PMC: 10297964. DOI: 10.3390/ijms24129962.


Purinergic signalling and cancer.

Burnstock G, Di Virgilio F Purinergic Signal. 2013; 9(4):491-540.

PMID: 23797685 PMC: 3889385. DOI: 10.1007/s11302-013-9372-5.


Neuropeptide Y receptors activation protects rat retinal neural cells against necrotic and apoptotic cell death induced by glutamate.

Santos-Carvalho A, Elvas F, Alvaro A, Ambrosio A, Cavadas C Cell Death Dis. 2013; 4:e636.

PMID: 23681231 PMC: 3674367. DOI: 10.1038/cddis.2013.160.


Distinct potentiation of L-type currents and secretion by cAMP in rat chromaffin cells.

Carabelli V, Giancippoli A, Baldelli P, Carbone E, Artalejo A Biophys J. 2003; 85(2):1326-37.

PMID: 12885675 PMC: 1303249. DOI: 10.1016/S0006-3495(03)74567-6.

References
1.
Mousli M, Bueb J, Bronner C, Rouot B, Landry Y . G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides. Trends Pharmacol Sci. 1990; 11(9):358-62. DOI: 10.1016/0165-6147(90)90179-c. View

2.
Lotersztajn S, Pavoine C, Brechler V, Roche B, Dufour M, Le-Nguyen D . Glucagon-(19-29) exerts a biphasic action on the liver plasma membrane Ca2+ pump which is mediated by G proteins. J Biol Chem. 1990; 265(17):9876-80. View

3.
Cheung D . Neuropeptide Y potentiates specifically the purinergic component of the neural responses in the guinea pig saphenous artery. Circ Res. 1991; 68(5):1401-7. DOI: 10.1161/01.res.68.5.1401. View

4.
Anderson R, Breckon R, Dixon B . ATP receptor regulation of adenylate cyclase and protein kinase C activity in cultured renal LLC-PK1 cells. J Clin Invest. 1991; 87(5):1732-8. PMC: 295279. DOI: 10.1172/JCI115191. View

5.
Norenberg W, Illes P, Takeda K . Neuropeptide Y inhibits nicotinic cholinergic currents but not voltage-dependent calcium currents in bovine chromaffin cells. Pflugers Arch. 1991; 418(4):346-52. DOI: 10.1007/BF00550872. View